Announced details
Prescription data entry at pharmacies, dispensing operations, and registration in claims-processing computers
Average turnaround time of no more than 2 minutes and data entry accuracy of at least 99% (as of the interim evaluation of the proof-of-concept trial)
Group company. A wholly owned subsidiary of EMシステムズ
302, Onden Flat, 1-10-9 Jingumae, Shibuya-ku, Tokyo; Representative Director and President Kobayashi Daigo (小林大悟); development of automated prescription data entry systems for pharmacies and outsourced data entry services; capital ¥100 million; 100% owned by EMシステムズ
Positioned as a concrete step toward increasing product added value and wallet share under the medium-term management plan. The direct monetary impact on financial results is Not disclosed
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Prescription data entry service integrated with プレカル (commercial version) |
| Counterparty | 株式会社プレカル |
| Counterparty overview | 302, Onden Flat, 1-10-9 Jingumae, Shibuya-ku, Tokyo; Representative Director and President Kobayashi Daigo (小林大悟); development of automated prescription data entry systems for pharmacies and outsourced data entry services; capital ¥100 million; 100% owned by EMシステムズ |
| Relationship with the Company | Group company. A wholly owned subsidiary of EMシステムズ |
| Launch date | December 2026 (target release) |
| Applicable area | Prescription data entry at pharmacies, dispensing operations, and registration in claims-processing computers |
| Quantitative Effects | Average turnaround time of no more than 2 minutes and data entry accuracy of at least 99% (as of the interim evaluation of the proof-of-concept trial) |
| Impact on Business Performance | Positioned as a concrete step toward increasing product added value and wallet share under the medium-term management plan. The direct monetary impact on financial results is Not disclosed |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The interim evaluation of the proof-of-concept trial confirmed an average turnaround time of no more than 2 minutes and accuracy of at least 99%. In addition, the commercial version will be positioned not as a one-off proof of concept but as a core product in the dispensing segment, with the aim of increasing product added value and wallet share.